Aberrant activity of Rho small G-proteins and their regulators plays an important role in tumorigenesis. Rho guanine nucleotide exchange factor 10-Like (ARHGEF10L) is a member of the RhoGEF family that promotes the active GTP-bound state of Rho GTPases. This study used the Illumina GoldenGate microassay, Sequenom MassARRAY and TaqMan to analyze possible correlations between tag single nucleotide polymorphisms (tag SNPs) in the ARHGEF10L locus and various tumor risks. The genotyping analyses demonstrated a strong association of rs2244444 and rs12732894 with liver cancer. Western blotting and immunohistochemistry also revealed increased expression of ARHGEF10L in hepatocellular carcinoma tissues. Furthermore, increased cell proliferation, cell migration and RhoA activity; increased expression of Rho-associated coiled-coil kinase-1 (ROCK1), phospho-Ezrin/Radixin/Moesin (ERM), vimentin, N-cadherin and Slug, and decreased E-cadherin expression were detected in hepatocellular carcinoma cell Bel-7402 and HepG2 cells with transfection of ARHGEF10L-expressing plasmids. Opposite results were obtained in the two cell lines with transfection of anti-ARHGEF10L siRNA. Tumor-bearing mice were generated with Bel-7402 cells transfected with lentivirus vectors packaging short hairpin ARHGEF10L RNA. The xenograft tumors with the inhibited ARHGEF10L expression showed decreased tumor growth and expression of vimentin, N-cadherin and Slug. Additionally, decreased phospho-ERM expression was detected in Bel-7402 and HepG2 cells with transfection of anti-ROCK1 siRNA and increased expression of ROCK1 was detected in hepatocellular carcinoma tissues. E-cadherin, vimentin, Ncadherin and Slug are markers of the epithelial-to-mesenchymal transition (EMT). ROCK1, phospho-ERM and EMT have been reported to promote tumor cell proliferation, metastasis and angiogenesis. Our study suggests that increased expression of ARHGEF10L stimulates hepatocellular tumorigenesis by activating the RhoA-ROCK1-phospho ERM pathway and EMT.
Introduction
The Ras homologous (Rho) small GTPase family contains 20 human members, of which the most extensively characterized are the Rac1, RhoA and Cdc42 proteins. Rho family GTPases are critical regulators of cellular functions that play important roles in cancer progression. Aberrant activity of Rho small G-proteins and their regulators are hallmarks of cancer [1, 2] . Rho family guanine nucleotide exchange factors (RhoGEFs) promote the formation of the active GTP-bound state of Rho GTPases. The Dbl family is largest family of RhoGEFs with 70 human members, each of which activates distinct signaling in Rho activation [3] . The RhoA-specific GEF, GEF-H1, accelerates tumor cell proliferation upon transcriptional activation by expressing mutant p53 proteins in several cancers [4, 5] . Rho guanine nucleotide exchange factor 10-Like1 (ARHGEF10L), a member of the RhoGEF family, contains the typical Dbl homology domain, a putative WD40-like domain, and two predicted transmembrane helices. ARHGEF10L can induce GDP/GTP exchange at RhoA, but not at Rac1 or Cdc42 [6] . To date, no reports have been published regarding the involvement of ARHGEF10L in the tumorigenic process.
In this study, we first investigated possible association between candidate single nucleotide polymorphisms (SNPs) in the ARHGEF10L locus and various tumors. We then focused on investigating ARHGEF10L expression in the targeted tumor tissues based on the genotyping results. We also observed the effects of ARHGEF10L on cell proliferation and migration in cultured tumor cells as well as on tumor growth in xenograft models of tumors in mice. In addition, we investigated the downstream pathway of ARHGEF10L in tumorigenesis.
Materials and methods

Tissue collection
Solid tissue samples and blood samples were collected at Shandong Provincial Qianfoshan Hospital. Tumor diagnosis was verified by histological methods according to the World Health Organization (WHO) classification system. The work described has been carried out in accordance with the Ethical Principles for Medical Research Involving Human Subjects (World Medical Association Declaration of Helsinki). The study methodologies conformed to the standards set by the Declaration of Helsinki. All patients provided informed consent, and the study was approved by the Ethics Committee at Shandong Provincial Qianfoshan Hospital (Approval number 2015005).
Genotyping using Illumina 384-SNP VeraCode microarrays
Tag single nucleotide polymorphisms (tag SNPs) across the ARHGEF10L locus were identified by searching the HapMap database. The Illumina Assay Design Tool was used to filter out SNPs that were not suitable for the Illumina platform. After filtering, 13 SNPs in the ARHGEF10L gene were selected, specifically rs2245148, rs35812446, rs12732894, rs12756041, rs10788678, rs1193340, rs1193339, rs10888045, rs74059378, rs12117763, rs12562076, rs3766307 and rs35255680. The 13 SNPs were genotyped using a custom-designed Illumina 384-SNP VeraCode microarray (Illumina).
Peripheral blood samples were collected from patients with various tumors. Genomic DNA was extracted from whole blood samples with an Omega E-Z 96 Blood DNA kit (Omega Bio-Tek, USA). This kit incorporates the reversible nucleic acid-binding properties of HiBind® matrix in a high-throughput 96-well format to eliminate proteins, nucleases and other enzyme inhibitors or contaminators from blood or body fluids. Genotyping was conducted with a BeadXpress Reader using an Illumina VeraCode GoldenGate Assay kit.
Genotyping using a Sequenom MassARRAY
Seven SNPs (rs10888045, rs3753378, rs2244444, rs12067869, rs78944230, rs12562076 and rs3766307) across the ARHGEF10L locus were genotyped using an allele-specific MALDI-TOF mass spectrometry assay (Sequenom MassARRAY, Sequenom, San Diego, CA) in an independent case-control study. Peripheral blood samples were collected from patients with various tumors. Genotyping was performed using the Sequenom MassARRAY iPLEX platform.
TaqMan genotyping
SNPs at rs10888045, rs2244444, rs74059378 and rs12732894 were genotyped in independent cohorts of patients with various tumors. The assays were performed on a ViiA 7 DX (Life Technology) and evaluated according to the manufacturer's instructions. Reactions were carried out in a total volume of 10 µl using the following amplification protocol: denaturation at 95°C for 10 min, followed by 50 cycles of denaturation at 95°C for 15 s and annealing and extension at 60°C for 1 min. The genotype of each sample was determined by measuring allele-specific fluorescence using TaqMan Genotyper software V1.2 (Life Technology). The SNPs were analyzed for associations by comparing the minor allele frequencies (MAFs) between the cases and controls. Dominant and recessive models were considered with respect to the minor allele. Fisher's exact test was used for comparisons between categorical variables. Statistically significant differences were indicated by p values less than 0.05. Genotypic association was assessed using Plink v1.07 (http:// pngu.mgh.harvard.edu/purcell/plink/) and SHEsis (http://analysis. bio-x.cn/myAnalysis.php) software [7] [8] [9] . Bonferroni single-step correction was performed with Plink v1.07.
Western blot analysis
Hepatocellular carcinoma (n = 8, 3 females; 45-74 years old, mean 52 years old) tissue samples and tissues adjacent to the tumors were collected. The samples were individually homogenized in cell lysis solution (Beyotime Biotech, Shanghai, China). Supernatants were collected and their protein concentrations were determined using a BCA protein assay kit (Solarbio, Beijing, China). Total protein was separated by SDS-PAGE, transferred onto a polyvinylidene membrane and probed with antibodies. GAPDH (Proteintech Group, USA) was used to normalize sample loading. ARHGEF10L antibody was purchased from Sigma (St. Louis, USA); the antibody against VEGF was obtained from BOSTER (Wuhan, China); antibodies against Rho-associated coiled-coil kinase-1(ROCK1), vimentin, Slug, phospho-Ezrin (Thr567)/Radixin (Thr564)/Moesin (Thr558) and Ezrin/Radixin/Moesin were purchased from Cell Signaling (St. Louis, USA); the antibody against Rho-associated coiled-coil kinase-2 (ROCK2) was obtained from Abcam (Cambridge, MA, USA); and antibodies against N-cadherin and E-cadherin were obtained from Proteintech Group (USA).
Real-time PCR
Total RNA was extracted from Bel-7402 cells and then reversetranscribed to cDNA using an RNA PCR Kit (TOYOBO, Japan). Relative mRNA expression was calculated using the comparative threshold cycle (Ct) method. Relative target gene levels were normalized to the GAPDH mRNA level. Forward primer and reverse primer sequences for the amplification were as follows: ARHGEF10L, 5′-AGTGCCAGGTGGTGTT CTTC-3′ and 5′-AAGAGGTCCCCGATCTTCTC3-', and GAPDH (glyceraldehyde-3-phosphate dehydrogenase), 5′-CAGAACATCATCCCTGCCT CTAC-3′ and 5′-TTGAAGTCAGAGGAGACCACCTG-3′.
Immunohistochemistry
Tissue arrays were commercially obtained from Alenabio (Xian, China). The array slides contained 36 hepatocellular carcinoma samples and 8 normal tissue samples. Immunoreactivity was examined using an UltraSensitive TM S-P Kit (Maixin-Bio, China). The expression level of ARHGEF10L in the tumor tissue sections was semi-quantified using Chiew-Loon Koo's modified semiquantitative scoring system [10] .
siRNA interference and transfection
The siRNA oligonucleotides targeting the ARHGEF10L gene (target sequence: 5′-CCGCGTGAAGGAGATCCTGCA-3′) were designed and synthesized by QIAGEN (Germany). The siRNA oligonucleotides targeting the ROCK1 gene (target sequence: 5′-GGUAUAUGCUAUGAAGC UUTT-3′) were designed and synthesized by GenePharma (Shanghai, China). Cultured Bel-7402 and HepG2 cells were transfected with siRNA using the HiPerFect Transfection Reagent (QIAGEN, Germany). Allstars siRNA, which has no target sequence in human genes, was used as a control.
ARHGEF10L-expressing plasmid construction and transfection
The full sequence of ARHGEF10L was generated with PCR using the specific primers AscI-Fex, TACTCAGGCGCGCCTGATGGCTTCCTCCAA CCCT, and KpnI-Rex, TACTCAGGTACCTAGCATCAAGGGCACCTG. The PCR product was then sequenced and inserted into the AscI/KpnI sites of the pcDNA 3.1(+)-RFP (red fluorescent protein) expression vector. The ARHGEF10L-overexpressing plasmid was then transfected into Bel-7402 and HepG2 cells using PolyJet™ In Vitro DNA Transfection Reagent (SignaGen, USA). A pcDNA 3.1(+)-RFP expression vector without the cDNA insert (mock) was used as a control plasmid.
Cell proliferation assay
Bel-7402 and HepG2 cells were incubated for 2-4 h after the addition of 10 µl of Cell Counting Kit-8 (Dojindo, Japan) solution. Absorbance was measured at 450 nm with a spectrophotometer (Spectramax 190, Molecular Devices). This experiment was replicated three times.
Colony formation assay
After transfection, Bel-7402 and HepG2 cells were seeded and cultured in 60 mm cell culture dishes for two weeks. Colonies (≥ 50 cells) were then fixed with methanol for 15 min and stained with 1% crystal violet stain for 20 min. This experiment was replicated three times.
Transwell migration assay
Transwell inserts (Costar®, Corning, USA) were used to examine the effect of ARHGEF10L gene expression on cell migration. Transfected Bel-7402 and HepG2 cells were suspended in serum-free media and added to the upper chambers. After incubation for 24 h, each filter was immersed in methanol for 15 min at room temperature and then treated with 0.25% crystal violet stain for 10 min. The cells were counted with an inverted fluorescence microscope. This experiment was biologically replicated three times.
Generation of tumor-bearing mice using Bel-7402 cells
BALB/c nude mice (Vital River, Beijing, China) were used to prepare a tumor-bearing animal model. Bel-7402 cells were infected with a lentivirus vector (LV3-GFP&Puro) packing shARHGEF10L that was purchased from GenePharma (Shanghai, China). The target sequence of shARHGEF10L was CCGCGTGAAGGAGATCCTGCA. Cells transfected with blank vector were used as a control. Bel-7402 cells (6 × 10 6 ) suspended in 200 µl of PBS were subcutaneously injected into the right flank of mice to generate tumor-bearing BALB/c nude mice (n = 5, repeated three times). Mice were sacrificed after 30 days. The experiments were performed in accordance with the Regulations for the Administration of Affairs Concerning Ex-Perimental Animals of P. R. CHINA (2017). This study was approved by the Ethics Committee at Shandong Provincial Qianfoshan Hospital (Approval number 2015005).
Magnetic resonance imaging (MRI) studies
MRI was used to observe tumor growth using a small animal birdcage coil with a 3.0 T MRI scanner (Discovery 750, GE Healthcare, Waukesha, WI, USA). Diffusion weighted imaging (DWI) analysis was used to measure tumor growth in tumor-bearing mice with a T2-weighted (T2W) spin-echo (SE). DWI is a noninvasive method that detects the diffusion of water molecules in living tissue. Abnormal highsignal regions (bright region) in DWI indicate clear dispersion of tumor tissue. Apparent diffusion coefficients (ADCs) were obtained from DWI with the parameters that are listed in Table 1 . A decrease in the ADC indicates increased cell swelling and density, resulting in a smaller extracellular space, decreased water content and distorted extracellular structures, which suggests the vigorous proliferation and high activity of tumor cells. Low-signal regions (blue) in the pseudocolor ADC map show the results of a quantitative analysis of dispersion constraints in tumor tissues.
Rho activation assay
A Rho activation assay kit was obtained from Cytoskeleton (Denver, USA). Cultured Bel-7402 cells were collected and mixed with ice-cold cell lysis buffer (1X Protease Inhibitor Cocktail). The lysates were immediately clarified by centrifugation at 10,000×g for 1 min at 4°C. Equivalent protein amounts of cell lysate and rhotekin-RBD beads were mixed and then incubated for 60 min at 4°C on a rotator. The mixture was centrifuged at 5000×g at 4°C for 1 min. The beads were washed with Wash Buffer and then centrifuged at 3000 ×g at 4°C for 3 min. The beads were resuspended with 2X Laemmli sample buffer and boiled for 5 min. The protein samples were then analyzed by Western blotting with the anti-RhoA, anti-RhoB or anti-RhoC antibodies in the kit. This experiment was biologically replicated three times.
Immunofluorescence
Transfected Bel-7402 and HepG2 cells were seeded onto sterile glass coverslips. Cells were fixed with 4% paraformaldehyde, permeabilized with 0.2%Triton X-100, blocked with goat serum and incubated with primary antibodies against E-cadherin, N-cadherin or vimentin (Cell Signaling Technology, USA). The second day, the secondary antibody Alexa Fluor ™ 488 goat anti-rabbit IgG (Life Technologies Corporation, USA) was added, and DAPI was used to stain cell nuclei. Immunofluorescence images were captured using a fluorescence microscope.
Statistical analysis
Student's t-test was used to evaluate the statistical significance of differences between two groups. Statistical differences were considered significant when p < 0.05. When the patient and mice data were analyzed, the confirmation of normal distribution was considered. The measured value for the study groups was presented as the mean ± SD. The Kolmogorov-Smirnov (K-S) test was performed to test whether the data followed a normal distribution.
Results
Determining the genetic associations between ARHGEF10L genes and tumor risks
Thirteen tag SNPs in the ARHGEF10L gene were genotyped in this study using an Illumina 384-SNP VeraCode microarray. The SNP at rs35812446 showed significant differences in allelic frequency and genotypic frequency between the esophageal carcinoma cohort, the liver cancer cohort and the healthy controls. rs12732894 was significantly different in both allelic frequency and genotypic frequency between liver cancer cases and controls and in genotypic frequency between rectal carcinoma cases and controls; rs10788678 showed Table 2 Genotyping result of illumina microarray (control n = 384). significant differences in allelic frequency between the cervical carcinoma cohort and controls. rs10888045 showed significant differences in allelic frequency between breast cancer cases and controls and in allelic frequency and genotypic frequency between cervical carcinoma cases and controls. rs74059378 was significantly different in allelic frequency and genotypic frequency between breast cancer, liver cancer, and cervical carcinoma cases and controls. rs12562076 showed significant differences in allelic frequency and genotypic frequency between liver cancer and cervical carcinoma cases and controls. rs3766307 showed significant differences in allelic frequency and genotypic frequency between the breast cancer cohort and the controls. rs35255680 showed significant differences in allelic frequency between the breast cancer cohort and controls. These results are shown in Table 2 .
To verify the Illumina microarray genotyping results, seven SNPs across the ARHGEF10L locus were genotyped in an independent casecontrol study using a Sequenom MassARRAY. The case-control analysis showed a significant difference in both allelic frequency and genotypic frequency for rs2244444 between liver cancer patients and controls, as well as a significant difference in genotypic frequency for rs12067869 between cervical carcinoma and healthy controls. These results are shown in Table 3 . Following multiple-test correction, these two SNPs remained significantly different in their allelic frequency and genotypic frequency.
Four SNPs across the ARHGEF10L locus were genotyped using the TaqMan genotyping method. rs2244444 was significantly different in allelic frequency and genotypic frequency between liver cancer cases and controls. rs12732894 showed significant differences in allelic frequency between the liver cancer cohort and controls. Following multiple-test correction, these two SNPs still showed significant differences in their allelic frequency and genotypic frequency between the cases and controls. These results are shown in Table 4 .
Determining ARHGEF10L expression in liver tumor tissues
Western blot analysis with GAPDH as a reference revealed that all 8 hepatocellular carcinoma samples expressed more ARHGEF10L than their peritumoral tissue samples at a molecular weight of 120 kDa ( Fig. 1A and B) . Immunohistochemistry was performed to detect ARHGEF10L expression in a panel of hepatocellular carcinoma tumor tissues. ARHGEF10L expression was observed in tumor tissue samples in the T2 stage (n = 16) and T3 stage (n = 20) (Fig. 1C and D) . ARHGEF10L expression was also detected in approximately 50% of normal hepatic tissues (n = 8), but the density of the immune signal was much lower than that in the tumor tissues (Fig. 1E) . The expression level of ARHGEF10L in tumor tissue sections was quantified using Chiew-Loon Koo's-modified semi-quantitative scoring system. ARH-GEF10L was significantly more highly expressed in hepatocellular carcinoma tumor tissues at the T2 and T3 stages than in normal hepatic tissues (Fig. 1F) . Patient information for immunohistochemistry is shown in Supplementary Table 1.
Determining the effect of ARHGEF10L expression on the proliferation and migration of Bel-7402 and HepG2 cells
Western blot analysis revealed a significantly lower ARHGEF10L protein expression in cultured Bel-7402 and HepG2 cells transfected with anti-ARHGEF10L siRNA ( Fig. 2A and C) . ARHGEF10L protein expression was significantly higher in Bel-7402 and HepG2 cells with transfection of ARHGEF10L-expressing plasmids (Fig. 2B and D) . Because the ARHGEF10L protein was overexpressed with RFP tag, its immune-signal in transfected cells was at molecular weight of 150 kDa. Another signal at a molecular weight of 120 kDa was ARHGEF10L protein that was originally produced in the cells.
The proliferation of Bel-7402 and HepG2 cells was measured using CCK-8 assays and colony formation assays. Significantly less cell proliferation was detected in Bel-7402 and HepG2 cells subjected to anti-ARHGEF10L siRNA transfection for 48 h and 72 h, indicating that the inhibition of ARHGEF10L expression significantly retards cell proliferation ( Fig. 3A and C) . The CCK-8 assays also detected significantly more cell proliferation in Bel-7402 and HepG2 cells transfected with ARHGEF10L-expressing plasmids for 48 h and 72 h, indicating that increased ARHGEF10L expression significantly stimulates cell proliferation ( Fig. 3B and D) . Colony formation assays demonstrated that knocking -down ARHGEF10L expression decreased the numbers of colonies in Bel-7402 and HepG2 cells (Fig. 3E and G) ，whereas the overexpression of ARHGEF10L significantly increased the numbers of colonies in Bel-7402 and HepG2 cells (Fig. 3F and H) .
The cell migration ability of Bell-7402 and HepG2 was measured using the transwell system. Cell migration was significantly delayed in anti-ARHGEF10L siRNA-transfected Bel-7402 and HepG2 cells compared to the Allstars siRNA-transfected cells (Fig. 4A and C) , indicating that the inhibition of ARHGEF10L expression significantly delays cell migration. When Bel-7402 and HepG2 cells were transfected with the ARHGEF10L-expressing plasmids, their migration was significantly promoted (Fig. 4B and D) , indicating that overexpression of ARH-GEF10L significantly elevates cell migration ability.
Determining the effect of ARHGEF10L expression on tumor growth in tumor-bearing mice
Bel-7402 cells transfected with lentivirus packaging shARHGEF10L vectors were injected into nude mice to generate liver tumors. Realtime PCR detected significant decreases in ARHGEF10L mRNA levels in Bel-7402 cells transfected with shARHGEF10L (Fig. 5A) . The average tumor volume in mice injected with Bel-7402 cells transfected with shARHGEF10L was 613.3 mm 3 , while the tumor volume of control group was 918.4 mm 3 ( Fig. 5B and C) . Mouse tumors that originated from shARHGEF10L-transfected Bel-7402 cells show less DWI signal density than the tumors from blank vector-transfected cells. The ADC of tumor tissues generated with shARHGEF10L-transfected Bel-7402 cells was significantly higher than that of the control group ( Fig. 5D and E) . These results demonstrate that the inhibition of ARHGEF10L expression in liver tumor tissues can significantly suppress cell activity and tumor growth in tumor-bearing tissues in vivo. Additionally, our histochemistry showed that tumors in mice injected with shARHGEF10L-transfected Bel-7402 cells exhibited lower cell densities, lacked compact tissue structures and showed many apoptotic-like cells (Fig. 5F ). These results are in accordance with the MRI analysis.
Determination of the pathogenic pathway of ARHGEF10L in liver cancer
We conducted Rho activation assays to determine the pathogenic pathway of ARHGEF10L in liver cancer. Using the anti-RhoA antibody, an immuno-signal was much stronger in Bel-7402 cells with transfection of the ARHGEF10L-expressing plasmids than in the cells transfected with mock plasmids (Fig. 6A) . When the anti-RhoB antibody or anti-RhoC antibody was used to detect total protein from Bel-7402 cells, the immuno-signals were relatively low, and there was no significant difference between two the groups of cells (Fig. 6A) . Overexpressing ARHGEF10L also strengthened the immuno-signal of GTP-RhoA in HepG2 cells (Fig. 6B) . These results indicate that recombinant ARH-GEF10L has GEF activity and can activate RhoA but not RhoB or RhoC.
We investigated the expression level of ROCK1, the downstream effector in RhoA signaling. Western blotting revealed increased ROCK1 expression (160 kDa) in ARHGEF10L -plasmid transfected Bel-7402 and HepG2 cells (Fig. 6C and D) . Conversely, Bel-7402 and HepG2 cells transfected with anti-ARHGEF10L siRNA showed decreased expression of ROCK1 ( Fig. 6C  and D) . These results demonstrated that ARHGEF10L regulates ROCK1 expression. We also investigated the ROCK2 protein expression in Bel- Table 3 Genotyping result of Sequenom MassARRY (control n = 760). Table 4 Taqman genotyping result (control n = 288). 7402 and HepG2 cells. ARHGEF10L had no effect on ROCK2 expression ( Supplementary Fig. 1 ). In addition, we detected the ROCK1 protein expression level in hepatocellular carcinoma (n = 8). ROCK1 protein exhibited higher expression in hepatocellular carcinoma than peritumoral tissues (Fig. 6E and F) . We further examined phospho-Ezrin/ Radixin/Moesin (ERM) protein which plays an important role in cell adhesion. Western blotting revealed increased phospho-ERM protein expression (75 kDa, 80 kDa) in Bel-7402 and HepG2 cells with transfection of ARHGEF10L-expressing plasmids ( Fig. 7A and C) . In contrast, these cells showed decreased expression of phospho-ERM protein following transfection of anti-ARHGEF10L siRNA ( Fig. 7B and D) . To further investigate the influence of ROCK1 on phospho-ERM protein expression，we knocked down ROCK1 expression with siRNA in Bel-7402 and HepG2 cells. We found that inhibition of ROCK1 expression reduced the expression of phospho-ERM protein in Bel-7402 and HepG2 cells ( Fig. 7E and F) .
We next investigated the effects of ARHGEF10L on the epithelialmesenchymal transition (EMT). In the xenograft tumor mouse model (n = 5), the levels of vimentin, N-cadherin, Slug and VEGF were lower in tumors that were generated with shARHGEF10L-transfected Bel-7402 cells than in the controls (Fig. 8A) . However, the E-cadherin expression level did not change.
Compared with cells transfected with mock plasmids, both Bel-7402 and HepG2 cells transfected with ARHGEF10L-expressing plasmids showed upregulated vimentin, N-cadherin and Slug, while the expression of epithelial marker E-cadherin was down-regulated ( Fig. 8B and  C) . In contrast, the protein levels of E-cadherin were up-regulated, and the protein levels of vimentin, N-cadherin and Slug were down-regulated ( Fig. 8B and C) in Bel-7402 and HepG2 cells transfected with anti-ARHGEF10L siRNA.
Meanwhile, Bel-7402 and HepG2 cells transfected with ARHGEF10L-expressing plasmids lost cell-cell contacts and exhibited a fibroblastic-like morphology (Fig. 8D ). An immunofluorescence assay was also used to detect these EMT markers (E-cadherin, vimentin and N-cadherin) in Bel-7402 and HepG2 cells with transfection of anti-ARHGEF10L siRNA or ARHGEF10L expressing plasmids. ARHGEF10L knockdown increased E-cadherin expression and decreased the N-cadherin and vimentin expression levels in Bel-7402 and HepG2 cells ( Fig. 9A and C) . ARHGEF10L overexpression decreased E-cadherin expression and increased the N-cadherin and vimentin expression levels in Bel-7402 and HepG2 cells (Fig. 9B and D) . These results were similar to the above Western blot results and suggest that ARHGEF10L induces EMT in liver tumor cells and tumor tissues.
Discussion
Analysis of the microarray showed that rs35812446, rs12732894, rs74059378 and rs12562076 significantly differed in allelic frequency, genotypic frequency or both between the controls and cases of liver cancer. The Sequenom MassARRAY analysis also showed a significant difference in the allelic and genotypic frequencies of rs2244444 between liver cancer cases and controls. Furthermore, the TaqMan analysis showed that the allelic and genotypic frequencies of rs2244444 and the allelic frequency of rs12732894 were significantly different between liver cancer cases and controls. The above studies using different genotyping methods with independent cohorts provided strong evidence that rs2244444 and rs12732894 in the ARHGEF10L gene are strongly associated with liver cancer and that the ARHGEF10L-encoding gene is genetically susceptible to liver cancer risk. We thus focused on investigating the expression and pathogenic pathway of ARHGEF10L in liver tumors. As the tag SNPs rs2244444 and rs12732894 are located in an intron, in our next study, we will screen other SNPs in, e.g., exons and splice sites, as well as synonymous or nonsynonymous variants around these two tag SNPs to further investigate the relationships of the identified SNPs with the expression level or activity of ARHGEF10L.
Immunohistochemistry showed that ARHGEF10L expression was significantly higher in most hepatocellular carcinoma tissues, especially tissue samples at the T3 stage. Western blotting also detected increased ARHGEF10L protein expression in liver tumor tissues. CCK-8 assay, colony formation assays and a two-compartment transwell system demonstrated that ARHGEF10L overexpression significantly enhanced cell proliferation and migration ability in Bel-7402 and HepG2 cells. Bel-7402 cells transfected with shARHGEF10L via lentivirus packaging were subcutaneously injected into nude mice to generate mouse-burdened liver tumors. The average volume of tumors in the experimental group was much lower than that of tumors from cells transfected with blank LV3-GFP and Puro vectors. The ADC values of the tumors that were generated with shARHGEF10L-transfected Bel-7402 cells were significantly higher than that of the control group. Histochemistry also showed that mouse tumors with inhibited ARHGEF10L expression had low cell density, lacked compact tissue structure and displayed a great number of apoptotic-like cells. These results demonstrate that the inhibition of ARHGEF10L expression in a xenograft tumor mouse model can significantly retard tumor growth as well as its molecular activity. The ARHGEF10L expression level is related to tumor size and metastasis in a xenograft tumor mouse model. Based on the above observations, we hypothesize that the increased expression of ARHGEF10L in liver tumor tissues contributes to liver tumorigenesis by stimulating cell proliferation and cell migration.
The EMT contributes to increased invasiveness and metastasis as well as, resistance to therapies, and is therefore deeply involved in tumor progression. Vimentin is used as a marker of mesenchymally derived cells or cells undergoing EMT [11] . N-cadherin mediates strong cell-cell adhesion and induces cell migration in EMT [12] . E-cadherin, also a hallmark of EMT, is expressed in most normal epithelial tissues [13, 14] . Slug, a zinc finger transcriptional factor, has been shown to repress the transcription of E-cadherin [15] . We detected upregulated expression of vimentin, N-cadherin and Slug in Bel-7402 and HepG2 cells with ARHGEF10L overexpression. We also detected decreased Ecadherin expression in Bel-7402 and HepG2 cells with ARHGEF10L overexpression and increased expression in cells with inhibited ARH-GEF10L expression. Furthermore, down-regulated expression of vimentin, N-cadherin and Slug was detected in cells with inhibited ARHGEF10L expression and in mouse-bearing tumors from Bel-7402 cells with knocked-down ARHGEF10L expression. Our in vivo and in vitro data demonstrate that ARHGEF10L upregulated vimentin, Ncadherin and Slug expression and down-regulated E-cadherin expression to promote the EMT. In this study, we did not detect a significant change in E-cadherin expression in mouse-bearing tumors that originated from Bel-7402 cells. This result may be due to differences in the microenvironments of animal tissues and cell cultures. The cell culture microenvironment, which contains identical cells, is much simpler than that of tissues with different types of cells in vivo. ARHGEF10L may not primarily affect E-cadherin expression in animal tumor tissues. We detected decreased VEGF levels in mouse-bearing tumors that originated from Bel-7402 cells with inhibited ARHGEF10L expression. This result indicates that ARHGEF10L is involved in angiogenesis under in vivo conditions. We did not examine VEGF expression in cultured Bel-7402 and HepG2 cells because VEGF prompts vascular generation by Elevated RhoA/Rho kinase signaling promotes cancer development and metastasis [16] [17] [18] [19] . Our Rho activation assays indicated that recombinant ARHGEF10L can activate GTP-RhoA but not RhoB and RhoC in the cultured liver tumor cells. We hypothesize that the increased expression of ARHGEF10L led to constitutive activation of RhoA kinase activity to promote tumor pathogenesis. ROCK is a major downstream effector of the small GTPase RhoA. The ROCK family, consisting of ROCK1 and ROCK2, plays a central role in the organization of the actin cytoskeleton and is involved in a wide range of fundamental cellular functions such as contraction, adhesion, migration, proliferation, and apoptosis [20, 21] . Once activated, GTP-RhoA activates downstream effectors, including ROCK1 and ROCK2. Increased ROCK1 levels are associated with poor differentiation, metastasis, clinic pathologic parameters and patient survival in primary bladder tumors, metastatic breast tumors and osteosarcoma [22] [23] [24] [25] [26] . In this study, ROCK1 expression was increased in hepatocellular carcinoma tissues and Bel-7402 and HepG2 cells transfected with ARHGEF10L-expressing plasmids. We did not detect alternative expression of ROCK2 in the transfected cells. High ROCK1 expression has been reported in hepatocellular carcinoma tissues, and miR199-a/b-5p post-transcriptionally suppressed ROCK1. MiR-199 family members were downregulated in HCC tumors and cell lines, and low miR-199a/b-5p expression was associated with poor overall survival of hepatocellular carcinoma patients. MiR-199a/b-5p overexpression in HCC cell lines inhibited cell proliferation, migration and invasion, both in vitro and in vivo. That report supports our findings [27] . Furthermore, we detected increased phosphorylation of ERM in Bel-7402 and HepG2 cells with ARHGEF10L overexpression and decreased phosphorylation of ERM in the cells with inhibited ROCK1 expression. Phosphorylation of ERM that is activated with RhoA stimulates ROCK-mediated focal adhesion formation [28] . We suggest that the increased expression of ARHGEF10L activates RhoA and upregulates ROCK1 expression in liver tumors, and then stimulates ERM phosphorylation to induce tumorigenic processes such as tumor cell migration and metastasis.
In summary, the present study revealed the genetic susceptibility of ARHGEF10L to liver cancer risk and demonstrated the significantly higher expression of ARHGEF10L in liver tumor tissues. This study also found that ARHGEF10L stimulates the tumor cell proliferation and cell migration. The inhibition of ARHGEF10L expression significantly decreased tumor growth in a xenograft tumor mouse model. Furthermore, this study demonstrated that ARHGEF10L activates RhoA, upregulates ROCK1 expression and induces EMT. Our study suggests that increased expression of ARHGEF10L stimulates hepatocellular tumorigenesis by activating the RhoA-ROCK1-phospho ERM pathway and EMT. 
